Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. “Tim Pigot is an accomplished pharma industry business leader and a deeply res...
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. “During our second quarter of 2025, we continued to position the Company to advance IKT-001 towa...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Texas Capital Bancshares, Inc. Announces Second Quarter 2025 Results Second quarter 2025 net income of $77.3 million and net income available to common stockholders of $73.0 million, up 86% and 95%, respectively, year-over-year Second quarter 2025 EPS of $1.58 per diluted share and adjusted EPS(1) of $1.63 per diluted share, up 98% and 104%, respectively, year-over-year Strong balance sheet growth with total loans increasing 7% quarter-over-quarter and 10% year-over-year Book Value and Tangible Book Value(2) per share both increasing 13% year-over-year, reaching record levels DA...
Texas Capital Bancshares, Inc. Announces Date for Q2 2025 Operating Results DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the second quarter of 2025 before market on Thursday, July 17, 2025. Executive management will host a conference call and webcast to discuss second quarter 2025 operating results on Thursday, July 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to b...
Summary Southside Bancshares Inc - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Southside Bancshares Inc (SBSI) is a bank holding company operating through its subsidiary, Southside Bank, which provides a range of financial services. The company's main activities include o...
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments. “During our first...
Texas Capital Foundation Awards $250,000 to Texas Nonprofits Annual Honors Award program celebrates four organizations that are building a stronger Texas DALLAS, May 14, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the recipients of its 2025 Honors Awards. Launched in 2022, the Honors Awards are a signature initiative of the Texas Capital Foundation, awarding $250,000 in total annually to four organizations dedicated to addressing community needs across the state. “We are proud to honor four nonprofits as...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.